Abstract
EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.
Original language | English (US) |
---|---|
Pages (from-to) | 105-108 |
Number of pages | 4 |
Journal | Gynecologic oncology |
Volume | 56 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1995 |
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology